In a male prostate‑cancer patient who completed radiation therapy eight months ago, has EMG‑confirmed S1 radiculopathy, now presents with sudden bilateral toe and plantar foot numbness up to the mid‑heel that began overnight three and a half months ago, and whose prostate‑specific antigen has fallen from about eight to 1.15, is there any indication that a PSMA positron emission tomography/computed tomography scan would be advantageous over contrast‑enhanced lumbar magnetic resonance imaging for evaluating his current neurologic symptoms?

Neurologic Evaluation in Post-Radiation Prostate Cancer Patient

For this patient's sudden bilateral foot numbness, lumbar MRI is the appropriate imaging modality—not PSMA PET/CT—because the neurologic symptoms are most consistent with radiation-induced lumbosacral plexopathy or other structural spinal pathology, and PSMA PET/CT is designed to detect prostate cancer recurrence, not to evaluate peripheral nerve or plexus injury. 1, 2

Primary Concern: Radiation-Induced Neurologic Injury

The clinical presentation strongly suggests radiation-induced lumbosacral plexopathy rather than metastatic disease:

• Sudden overnight onset of bilateral symptoms 3.5 months ago is atypical for metastatic progression but consistent with radiation injury, which can manifest months to years after treatment 2
• Excellent PSA response (8.0 → 1.15) indicates effective cancer control, making active metastatic disease less likely 3
• Pre-existing S1 radiculopathy documented 5-6 months ago suggests evolving radiation-related nerve damage in the treatment field 2
• Bilateral distribution affecting both feet symmetrically is more characteristic of plexopathy or bilateral nerve root involvement from radiation fibrosis than from focal metastatic disease 2

Why MRI Over PSMA PET/CT

Lumbar spine MRI with contrast is the gold standard for evaluating:

• Radiation-induced lumbosacral plexopathy and fibrosis in the sacral nerve roots 2
• Pelvic insufficiency fractures (which commonly coexist with radiation plexopathy and can cause similar symptoms) 2
• Structural spinal pathology including disc herniation, stenosis, or other compressive lesions 4
• Differentiation between radiation changes and tumor recurrence in the pelvis/spine 1, 2

PSMA PET/CT has no role in evaluating peripheral neuropathy or plexopathy:

• PSMA imaging is designed to detect prostate cancer cells expressing PSMA, not to assess nerve injury or structural spinal disease 5, 6
• While PSMA PET/CT excels at detecting biochemical recurrence and metastatic disease, guidelines recommend it primarily for biochemical recurrence evaluation or staging—not for neurologic symptom workup 3, 1, 7
• The patient's falling PSA argues against active metastatic progression requiring PSMA imaging at this time 3

Critical Diagnostic Pitfall

Radiation-induced plexopathy can be mistaken for metastatic disease, but key distinguishing features include:

• Radiation plexopathy typically presents with progressive sensory symptoms, weakness, and pain developing months to years post-treatment 2
• MRI shows characteristic findings of fibrosis and enhancement in the radiation field without discrete mass lesions 2
• EMG/nerve conduction studies (already performed showing S1 radiculopathy) support nerve injury rather than metastatic compression 2

Additional Consideration

Pelvic insufficiency fractures should be actively sought on MRI, as they frequently coexist with radiation plexopathy and can contribute significantly to pain and functional impairment 2. These fractures occur in the radiation field and may not be clinically obvious without imaging.

When PSMA PET/CT Would Be Indicated

PSMA PET/CT would only become relevant if:

• PSA begins rising significantly, suggesting biochemical recurrence 3, 1, 7
• MRI reveals suspicious lesions requiring differentiation between post-radiation changes and tumor recurrence 1
• Planning salvage therapy for confirmed local or distant recurrence 1, 6

The neurologic symptoms themselves are not an indication for PSMA imaging 1, 2.